Security key
89422GAA5
- Security type / class
- Debt / NOTE 2.250% 3/0
- Reported market price (% of par)
- 95.39%
- Total 13F principal
- $279,664,978
- Principal change
- +$2,653,685
- Total reported market value
- $303,344,890
- Number of holders
- 26
- Value change
- +$1,782,692
- Number of buys
- 13
- Number of sells
- 14
Security identity
Holder snapshot
Report period
Q2 2025
Institutions
26
Top holders
10
89422GAA5 full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Broader feeds
Reporting periods
Holder history for CUSIP 89422GAA5
Recent filing periods:
Ownership snapshot
Top reported holders of 89422GAA5 - TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
—
13D/G signal
—
Evidence rows
0
Latest as of
—
No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
26
Principal
$279,664,978
Rows available
26
| Investor | Option | Weight % | Change % | Reported value | * Price (% of par) | Principal | Share Change | Activity | Report Period |
|---|
* Reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that failed the local validity check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
28
Q2 2025 holders
26
Holder diff
-2
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend